U.S. License Holder:
Genmab US, Inc.
Date of License:
May-19-2023
Last Update:
Dec-15-2024
FDA-Approved Indications
EPKINLY (epcoritamab-bysp) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of:
Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma: Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy;
Follicular Lymphoma: Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.